|
|
|
|
|
Prognostic Role of Immune-related Genes in Hepatocellular Carcinoma |
| WANG Jue, JIN Zongrui, WANG Wei, YI Qilin, WANG Jilong, ZHU Hai, XU Banghao, GUO Ya, WEN Zhang |
| Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China |
|
|
|
|
Abstract Abstract: Objective To identify the potential prognostic biomarkers of the immune-related genes signature for patients with hepatocellular carcinoma (HCC). Methods Original HCC data were downloaded from TCGA, and the immune activity of each sample was calculated by ssGSEA. HCC samples were divided into high and low immune cell infiltration groups by “GSVA” package and “hclust” package. The ESTIMATE algorithm scored the tumor microenvironment in each HCC sample. The “limma” package and Venn diagram identified effective immune-related genes. Univariate Cox, Lasso regression and multivariate Cox regression analyses were used to explore key genes. The “rms” package was used to create nomograms and draw calibration curves. Results Compared with the high immune cell infiltration group, the tumor purity of the samples in the low immune cell infiltration group was higher, the immune score, ESTIMATE score and stromal score were lower. In the high immune cell infiltration group, the immune components were more abundant, and the expression levels of TIGIT, PD-L1, PD-1, LAG3, TIM-3, CTLA4 and HLA family were higher. Multivariate Cox regression analysis showed that four immune-related genes (S100A9, HMOX1, IL18RAP and FCER1G) were used to construct the prognosis model. Compared with other clinical features, the risk score of this prognostic model was recognized as an independent prognostic factor. Conclusion This study identified the immune-related core genes which may be used in targeted therapy and immunotherapy of HCC.
|
| Keywords
Hepatocellular carcinoma
TCGA
Immune gene
Prognosis
|
|
|
| Fund:National Natural Science Foundation of China (No. 81902983, No. 81560387); Guangxi Natural Science Foundation (No. 2018JJB140382); “Medical Excellence Award” Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University (No. 180327); Guangxi Medical and Health Technology Development and Application Project (No. S2018100) |
|
Issue Date: 16 June 2022
|
|
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 1 85 countries[J]. CA Cancer J Clin, 2021, 71(3):
209-249.
[2] Nault JC, Villanueva A. Biomarkers for Hepatobiliary Cancers[J].
Hepatology, 2021, 73 Suppl 1: 11 5-127.
[3] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of
trends in cancer survival 2000-14 (CONCORD-3): analysis of
individual records for 37 513 025 patients diagnosed with one of
18 cancers from 322 population-based registries in 71 countries[J].
Lancet, 2018, 391(10125): 1023-1075.
[4] Our a K, Mor i shi t a A, Tani J , e t al . Tumor Immune
Microenvironment and Immunosuppressive Therapy in
Hepatocellular Carcinoma: A Review[J]. Int J Mol Sci, 2021,
22(11 ): 5801.
[5] 邹添添, 覃伟, 朱迎, 等. 肝癌免疫微环境与免疫治疗:研究进
展与发展趋势[J]. 中国普通外科杂志, 2020, 29(7): 785-797.
[Zou TT, Qin W, Zhu Y, et al. Immune microenvironment and
immunotherapy in hepatocellular carcinoma: research progress
and development directions[J]. Zhongguo Pu Tong Wai Ke Za
Zhi, 2020, 29(7): 785-797.]
[6] Singh A, Beechinor RJ, Huynh JC, et al. Immunotherapy Updates
in Advanced Hepatocellular Carcinoma[J]. Cancers (Basel), 2021,
13(9): 2164.
[7] Law AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-Derived
Suppressor Cells as a Therapeutic Target for Cancer[J]. Cells,
2020, 9(3): 561.
[8] Liu M, Zhou J, Liu X, et al. Targeting monocyte-intrinsic
enhancer reprogramming improves immunotherapy efficacy in
hepatocellular carcinoma[J]. Gut, 2020, 69(2): 365-379.
[9] Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal Dynamics
of Intratumoral Immune Cells Reveal the Immune Landscape in
Human Cancer[J]. Immunity, 2013, 39(4): 782-795.
[10] Gonnord P, Costa M, Abreu A, et al. Multiparametric analysis
of CD8+ T cell compartment phenotype in chronic lymphocytic
leukemia reveals a signature associated with progression toward
therapy[J]. Oncoimmunology, 2019, 8(4): e1570774.
[11 ] Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for
comparing biological themes among gene clusters[J]. OMICS,
2012, 16(5): 284-287.
[12] Liao X, Huang K, Huang R, et al. Genome-scale analysis to
identify prognostic markers in patients with early-stage pancreatic
ductal adenocarcinoma after pancreaticoduodenectomy[J]. Onco
Targets Ther, 2017, 10: 4493-4506.
[13] Giraud J, Chalopin D, Blanc JF, et al. Hepatocellular Carcinoma
Immune Landscape and the Potential of Immunotherapies[J].
Front Immunol, 2021, 12: 655697.
[14] Lim CJ, Lee YH, Pan L, et al. Multidimensional analyses reveal
distinct immune microenvironment in hepatitis B virus-related
hepatocellular carcinoma[J]. Gut, 2019, 68(5): 916-927.
[15] Bindea G, Mlecnik B, Galon J. Tumor spread or siege immunity:
dissemination to distant metastasis or not[J]. OncoImmunology,
2021, 10(1): 1919377.
[16] Hao X, Sun G, Zhang Y, et al. Targeting Immune Cells in the
Tumor Microenvironment of HCC: New Opportunities and
Challenges[J]. Front Cell Dev Biol, 2021, 9: 775462.
[17] Zhu S, Yi M, Wu Y, et al. Roles of tumor-associated macrophages
in tumor progression: implications on therapeutic strategies[J].
Exp Hematol Oncol, 2021, 10(1): 60.
[18] Fu Y, Liu S, Zeng S, et al. From bench to bed: the tumor immune
microenvironment and current immunotherapeutic strategies for
hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1):
396.
[19] Ruiz De Galarreta M, Bresnahan E, Molina-Sánchez P, et al.
β-Catenin Activation Promotes Immune Escape and Resistance
to Anti-PD-1 Therapy in Hepatocellular Carcinoma[J]. Cancer
Discov, 2019, 9(8): 11 24-11 41.
[20] El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients
with advanced hepatocellular carcinoma (CheckMate 040): an
open-label, non-comparative, phase 1 /2 dose escalation and
expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502.
[21] 吴占波, 任秀宝. 免疫检查点阻断剂在肝癌治疗中的研究进
展[J]. 肿瘤防治研究, 2016, 43(9): 811 -813. [Wu ZB, Ren XB.
Advance of Immune Checkpoint Inhibitors in Therapy of Liver
Cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2016, 43(9): 811 -813.]
[22] Fan ZP, Peng ML, Chen YY, et al. S100A9 Activates the
Immunosuppressive Switch Through the PI3K/Akt Pathway
to Maintain the Immune Suppression Function of Testicular
Macrophages[J]. Front Immunol, 2021, 12: 743354.
[23] Shi L, Zhao Y, Fei C, et al. Cellular senescence induced by S100A9
in mesenchymal stromal cells through NLRP3 inflammasome
activation[J]. Aging(Albany NY), 2019, 11 (21): 9626-9642.
[24] Jo SH, Heo WH, Son HY, et al. S100A8/A9 mediate the
reprograming of normal mammary epithelial cells induced by
dynamic cell-cell interactions with adjacent breast cancer cells[J].
Sci Rep, 2021, 11 (1): 1337.
[25] Zhao Z, Zhang C, Zhao Q. S100A9 as a novel diagnostic and
prognostic biomarker in human gastric cancer[J]. Scand J
Gastroenterol, 2020, 55(3): 338-346.
[26] 杜雪梅, 昌红, 孙焕英, 等. 钙离子结合蛋白S100A9在乳腺癌
中表达及临床意义[J]. 细胞与分子免疫学杂志, 2012, 28(6):
637-639. [Du XM, Chang H, Sun HH, et al. Expression and
clinical significance of calcium-binding protein S100A9 in breast
cancer[J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2012, 28(6):
637-639.]
[27] Huang M, Wu R, Chen L, et al. S100A9 Regulates MDSCs-
Mediated Immune Suppression via the RAGE and TLR4
Signaling Pathways in Colorectal Carcinoma[J]. Front Immunol,
2019, 10: 2243.
[28] Liao J, Li JZ, Xu J, et al. High S100A9 + cell density predicts a
poor prognosis in hepatocellular carcinoma patients after curative
resection[J]. Aging(Albany NY), 2021, 13(12): 16367-16380.
[29] Chiang SK, Chen SE, Chang LC, et al. A Dual Role of Heme
Oxygenase-1 in Cancer Cells[J]. Int J Mol Sci, 2018, 20(1): 39.
[30] 巫亚龙, 唐圣松. 血红素加氧酶-1的抗肿瘤细胞凋亡作用研
究进展[J]. 临床与病理杂志, 2016, 36(4): 496-500. [Wu YL,
Tang SS. Advances in apoptosis of heme oxygenase-1 anti-tumor
cell[J]. Lin Chuang Yu Bing Li Za Zhi, 2016, 36(4): 496-500.]
[31] Zou C, Zhang H, Li Q, et al. Heme oxygenase-1: a molecular
brake on hepatocellular carcinoma cell migration[J].
Carcinogenesis, 2011 , 32(12): 1840-1848.
[32] Mantovani A, Dinarello CA, Molgora M, et al. Interleukin-1 and Related Cytokines in the Regulation of Inflammation and
Immunity[J]. Immunity, 2019, 50(4): 778-795.
[33] Liu WW, Hu M, Wang YM, et al. Overexpression of
interleukin-18 protein reduces viability and induces apoptosis of
tongue squamous cell carcinoma cells by activation of glycogen
synthase kinase-3 beta signaling[J]. Oncol Rep, 2015, 33(3):
1049-1056.
[34] Fu L, Cheng Z, Dong F, et al. Enhanced expression of FCER1G
predicts positive prognosis in multiple myeloma[J]. J Cancer,
2020, 11 (5): 11 82-11 94.
[35] Chen L, Yuan L, Wang Y, et al. Co-expression network analysis
identified FCER1G in association with progression and prognosis
in human clear cell renal cell carcinoma[J]. Int J Biol Sci, 2017,
13(11 ): 1361-1372.
[36] Xu D, Wang Y, Zhou K, et al. Development and Validation of a
Novel 8 Immune Gene Prognostic Signature Based on the Immune
Expression Profile for Hepatocellular Carcinoma[J]. Onco Targets
Ther, 2020, 13: 8125-8140.
[37] Sabbatino F, Liguori L, Polcaro G, et al. Role of Human
Leukocyte Antigen System as A Predictive Biomarker for
Checkpoint-Based Immunotherapy in Cancer Patients[J]. Int J
Mol Sci, 2020, 21(19): 7295.
[38] 王静, 魏素菊. HLA-Ⅰ类在肺癌免疫治疗中相关研究进展[J].
中国免疫学杂志, 2021, 37(19): 2428-2432. [Wang J, Wei SJ.
Research progress of HLA-Ⅰin lung cancer immunotherapy[J].
Zhongguo Mian Yi Xue Za Zhi, 2021, 37(19): 2428-2432.]
[39] Akazawa Y, Nobuoka D, Takahashi M, et al. Higher human
lymphocyte antigen class I expression in early-stage cancer cells
leads to high sensitivity for cytotoxic T lymphocytes[J]. Cancer
Sci, 2019, 11 0(6): 1842-1852.
[40] Huang CY, Wang Y, Luo GY, et al. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular
Carcinoma[J]. J Immunother, 2017, 40(9): 323-333.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
